newsfilter
← Latest News
GlobeNewswire·

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

  • Tvardi Therapeutics announced financial & operating results for Q4 & full-year 2025, with cash runway extending into Q4 2026.
  • Topline data for the healthy volunteer study of next-generation STAT3 inhibitor TTI-109 is anticipated in Q2 2026.
  • Topline data for the Phase 2 REVERT LIVER CANCER trial of TTI-101 in hepatocellular carcinoma is expected in H2 2026 to allow for data maturation.
  • Additional analysis of the REVERT IPF Phase 2 trial showed TTI-101 achieved a 9.4% reduction in fibrosis score vs 2.4% for placebo & a 4.5-fold greater decline in IL-6.
  • Research & development expenses decreased to $18.0 million for full-year 2025 from $23.7 million in 2024, driven by lower clinical costs for TTI-101 offset by higher TTI-109 costs.
  • General & administrative expenses increased to $8.7 million for full-year 2025 from $4.5 million in 2024 due to professional fees from the merger with Cara Therapeutics.
  • Net loss for full-year 2025 was $18.2 million, down from $29.4 million in 2024.
  • Cash, cash equivalents & short-term investments totaled $30.8 million as of December 31, 2025.